SZSE:002603 has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SZSE:002603 has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Shijiazhuang Yiling Pharmaceutical Co's enterprise value is ¥27,372 Mil. Shijiazhuang Yiling Pharmaceutical Co's Revenue for the trailing twelve months (TTM) ended in Sep. 2024 was ¥8,109 Mil. Therefore, Shijiazhuang Yiling Pharmaceutical Co's EV-to-Revenue for today is 3.38.
The historical rank and industry rank for Shijiazhuang Yiling Pharmaceutical Co's EV-to-Revenue or its related term are showing as below:
During the past 13 years, the highest EV-to-Revenue of Shijiazhuang Yiling Pharmaceutical Co was 11.25. The lowest was 2.08. And the median was 3.76.
The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.
EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.
As of today (2024-12-28), Shijiazhuang Yiling Pharmaceutical Co's stock price is ¥16.31. Shijiazhuang Yiling Pharmaceutical Co's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was ¥4.85. Therefore, Shijiazhuang Yiling Pharmaceutical Co's PS Ratio for today is 3.36.
The historical data trend for Shijiazhuang Yiling Pharmaceutical Co's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shijiazhuang Yiling Pharmaceutical Co Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
EV-to-Revenue | Get a 7-Day Free Trial | 2.40 | 3.35 | 3.23 | 3.87 | 3.76 |
Shijiazhuang Yiling Pharmaceutical Co Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
EV-to-Revenue | Get a 7-Day Free Trial | 3.00 | 3.76 | 3.80 | 3.15 | 3.76 |
For the Drug Manufacturers - Specialty & Generic subindustry, Shijiazhuang Yiling Pharmaceutical Co's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Shijiazhuang Yiling Pharmaceutical Co's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Shijiazhuang Yiling Pharmaceutical Co's EV-to-Revenue falls into.
EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.
Shijiazhuang Yiling Pharmaceutical Co's EV-to-Revenue for today is calculated as:
EV-to-Revenue | = | Enterprise Value (Today) | / | Revenue (TTM) |
= | 27371.899 | / | 8109.076 | |
= | 3.38 |
Shijiazhuang Yiling Pharmaceutical Co's current Enterprise Value is ¥27,372 Mil.
Shijiazhuang Yiling Pharmaceutical Co's Revenue for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥8,109 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shijiazhuang Yiling Pharmaceutical Co (SZSE:002603) EV-to-Revenue Explanation
The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.
Shijiazhuang Yiling Pharmaceutical Co's PS Ratiofor today is calculated as:
PS Ratio | = | Share Price (Today) | / | Revenue per Share (TTM) |
= | 16.31 | / | 4.854 | |
= | 3.36 |
Shijiazhuang Yiling Pharmaceutical Co's share price for today is ¥16.31.
Shijiazhuang Yiling Pharmaceutical Co's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥4.85.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Shijiazhuang Yiling Pharmaceutical Co's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Zhang Qiu Lian | Directors, executives | |
Han Yue Zhi | Executives | |
Zhao Shao Hua | Executives | |
Wang Wei | Executives | |
Gao Xue Dong | Supervisors | |
Wu Yi Ling | Director | |
Gao Xiu Qiang | Executives | |
Wu Xiang Jun | Directors, executives | |
Guo Shuang Geng | Director | |
Wang Hua | Securities Affairs Representative | |
Dai Feng Xiang | Directors, executives | |
Liu Gen Wu | Supervisors | |
Wang Wei Ping | Directors, executives | |
Xu Wei Dong | Director | |
Wu Rui | Directors, executives |
No Headlines
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.